CRC Treatment Delays Linked to Increased Metastasis Risk

For oncology care teams, the coordination of care is often a race against time. While clinical guidelines provide clear therapeutic roadmaps for colorectal cancer (CRC), they have historically offered little guidance on the specific timing of treatment initiation. However, a new study published in JAMA Network Open suggests that even modest delays in care can significantly increase the risk of disease progression to metastasis.

The cohort study, which analyzed data from 11,927 insured patients with nonmetastatic CRC, found that the "tipping point" for metastatic progression varies significantly depending on the patient’s treatment pathway. For oncology nurses, these findings provide critical evidence-based benchmarks to advocate for timely interventions and to identify patients at the highest risk of falling through the cracks of a fragmented healthcare system.

Understanding pathway-specific thresholds

Researchers utilized machine learning to identify specific time-to-treatment initiation (TTI) thresholds—defined as the days from diagnosis to the first receipt of surgery, chemotherapy, or radiation. Rather than a "one-size-fits-all" deadline, the study demonstrated that metastasis risk is highly dependent on the sequence of care.

The study categorized patients into four primary pathways: surgery only, neoadjuvant therapy followed by surgery, surgery followed by adjuvant therapy, and trimodality therapy (neoadjuvant, surgery, and adjuvant).

The most striking findings occurred in the surgery plus adjuvant therapy group. In this pathway, delays of 4 to 46 days were associated with a 27% higher cumulative risk of metastasis compared to those treated within three days. When delays extended beyond 47 days, that risk jumped to 55%.

The nursing role in mitigating delays

Oncology nurses are uniquely positioned to address the administrative and systemic barriers that contribute to these delays. The study authors noted that while some delays reflect necessary preoperative evaluations, others stem from nonclinical bottlenecks such as prior authorization, insurance appeals, and scheduling hurdles.

For patients in the neoadjuvant plus surgery pathway, the study identified a significant risk increase at the 68-day mark. Delays in this group—which often includes patients with locally advanced tumors—can be particularly consequential.

Nurses can play a pivotal role here by coordinating multidisciplinary consultations and ensuring that patients facing transportation challenges, financial hardship, or comorbidity management issues receive the navigation support they need.

Interestingly, the study found no significant association between TTI and metastasis risk for patients in the trimodality pathway. Researchers suggested that the intensive, sequential nature of systemic therapy before and after surgery in this group might help suppress micrometastatic disease, effectively "offsetting" the impact of longer initiation times.

Clinical markers and "molecular tipping points"

The study also highlighted the importance of monitoring specific clinical markers. In the surgery-only group, radiation therapy within the first year was a strong indicator of higher underlying risk, showing a nearly threefold association with metastasis. This likely reflects more aggressive tumor biology that requires vigilant nursing follow-up.

Looking forward, the researchers discussed the potential of circulating tumor DNA (ctDNA) assays and other biomarkers to help clinicians identify when a patient is approaching a biological "tipping point" toward systemic dissemination. Until such tools are standard, oncology nurses remain the primary defense against avoidable delays.

Advocating for integrated care

The implications for nursing practice are clear: timely treatment is a cornerstone of value-based care. Because metastatic CRC imposes a much higher clinical and economic burden than early-stage disease—including more complex care requirements and a higher risk of toxic effects—preventing progression through prompt treatment is essential for patient sustainability.

The study authors recommend several strategies to reduce delays, many of which are led by nursing staff:

• Streamlined pathology workflows to expedite diagnosis-to-treatment intervals.
• Parallel consultations rather than sequential ones to move patients through the multidisciplinary pipeline faster.
• Enhanced patient navigation to address social determinants of health that cause postponements.
• Expedited insurance authorization processes to prevent administrative logjams.

"Ensuring prompt access to CRC treatment remains an evidence-based priority for improving patient outcomes," the study concluded. By understanding these pathway-specific thresholds, oncology nurses can better prioritize their caseloads and advocate for the systemic changes necessary to provide equitable, timely care for every patient.

Reference

Nguyen CM, Skaar TC, Imperiale TF, et al. Colorectal cancer treatment delay thresholds and metastasis risk. JAMA Netw Open. 2026;9(7):e2623057. doi:10.1001/jamanetworkopen.2026.23057